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Abstract In vitro studies revealed serotonin transporter
(5-HTT) decline in Parkinson’s disease (PD). Yet, few
studies investigated thalamic 5-HTT in vivo and its effect
on PD heterogeneity. We analyzed thalamic [
123I]b-CIT
binding (mainly reﬂecting 5-HTT binding) in 32 drug-
naı ¨ve PD patients and 13 controls with SPECT. Twenty-six
patients were examined twice (17 months apart). Based on
UPDRS scores, we identiﬁed subgroups of patients with
moderate/severe tremor (PDT) and without tremor (PDWT)
at the time of clinical diagnosis. Additionally, depressive
symptoms were evaluated using the Beck Depression
Inventory (BDI) at baseline. Mean thalamic speciﬁc to non-
speciﬁc [
123I]b-CIT binding ratio was lower in patients
when compared to controls, and further decreased during
follow-up. At baseline, average thalamic ratio was signif-
icantly lower in the PDT than in the PDWT subgroup. No
correlation was found between BDI scores and thalamic
binding ratios. Our ﬁndings show decline of [
123I]b-CIT
binding to thalamic 5-HTT in PD and its possible contri-
bution to tremor onset.
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Introduction
Degeneration of the dopaminergic system is still consid-
ered to be the pathological hallmark of Parkinson’s disease
(PD), although the serotonergic, cholinergic, noradrenergic
and gamma-amino-butyric acid systems are affected as
well (Hirsch et al. 2003). Importantly, when compared to
the dopaminergic circuitry, these systems may actually be
involved to a larger degree in the early stages of PD (Braak
et al. 2003). Abnormalities in non-dopaminergic systems
have now been implicated in the diversity of part of the
motor and non-motor symptomatology in PD (Chaudhuri
2006; de Rijk et al. 1997; Henderson et al. 2000b). In
particular, due to the widespread serotonergic innervations,
serotonin (5-HT) may play a role in regulating other neu-
rotransmitter activities (Fink et al. 2007). Post-mortem
neurochemical studies in PD have detected up to a 50%
5-HT loss in both the cortex and the basal ganglia brain
regions (Birkmayer et al. 1985, 1987; Scatton et al. 1983).
Moreover, neuronal loss and Lewy body formation not
only affect the dopaminergic neurons (Forno 1996) but also
the serotonergic system (Jellinger 1987). Whereas, loss of
5-HT in post-mortem PD studies is well established, its
degeneration in vivo and particularly its potential role in
affecting clinical PD presentation still awaits elucidation.
Various lines of evidence have suggested that 5-HT may
be involved in the etiology of resting tremor in PD. Loss of
striatal dopamine transporter (DAT) binding has been
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DOI 10.1007/s00702-007-0015-2shown to correlate with rigidity/bradykinesia, but not with
tremor (Spiegel et al. 2006) and, unlike rigidity and bra-
dykinesia the response of resting tremor to levodopa
therapy is variable at best (Koller et al. 1990). These
ﬁndings would argue against a pure dopaminergic etiology
of resting tremor. Since the late 1960s there has been
continuous debate over the genesis of tremor. Lesion
studies in animal models of parkinsonian tremor have
mainly targeted midbrain and cerebellar areas (Wilms et al.
1999), thereby mainly lesioning ascending serotonergic
projections to the forebrain. Tremor induced by harmaline
in rats and chickens can be effectively antagonized by 5-
HT supplementation (Bowman et al. 1968; Headley et al.
1976). It has been hypothesized that this tremorgenic
compound may act indirectly by inhibiting the inhibitory
serotonergic projections arising from the raphe nuclei
(Headley et al. 1976). Finally, decrease in midbrain 5HT-
1a receptors in PD along with an association with resting
tremor has been recently reported in a
11C-WAY 100635
PET study (Doder et al. 2003).
Selective neurodegeneration within the thalamus may
well contribute to the motor and non-motor symptoms of
PD (Henderson et al. 2000a, b). Noteworthy is thalamic
involvement in the extensive cerebral oscillatory network
that is postulated to determine resting tremor in PD,
as reported in various magnetoencephalograﬁc studies
(Schnitzler et al. 2006; Timmermann et al. 2003; Volk-
mann et al. 1996). Based on primate studies, experimental
tremor generated by a thalamo-cortical mechanism has
been deﬁned as a Parkinson-like tremor, whereas, the oli-
vo-cerebellar system was assessed to be responsible for the
faster ‘physiological’ tremor (DeLong 1978; Lamarre et al.
1975). In the 1980s deep brain stimulation (DBS) was ﬁrst
applied to the thalamus in patients with severe tremor
(Benabid et al. 1987). A multicenter European study
reported thalamic DBS to be effective on PD tremor, while
the other parkinsonian hallmarks did not receive consistent
beneﬁts (Limousin et al. 1999). Indeed, thalamic DBS is
recommended for patients disabled only by tremor (Lim-
ousin-Dowsey et al. 1999).
5-HT may also play a crucial role in the pathogenesis of
depression in PD. Several post-mortem studies as well as
biochemical studies of breakdown products of 5-HT in the
cerebral spinal ﬂuid (CSF) have shown reduced 5-HT
activity in the brain of PD patients (Birkmayer et al. 1987;
Kostic et al. 1987; Kuhn et al. 1996; Scatton et al. 1983).
Moreover, there is a functional polymorphism in the 5-HT
transporter (5-HTT) synthesis, and the short allele (which
synthesizes less 5-HTT) is associated with PD depression
(Mossner et al. 2001). Clinically, treatment with selective
5-HT reuptake inhibitors (SSRI), e.g., citalopram, improves
PD depressive symptoms (Antonini et al. 2006), although a
role for dopaminergic drugs has also been suggested
(Barone et al. 2006). Interestingly, a [
123I]b-CIT SPECT
study showed the capability of citalopram to block thalamic
5-HTT in depressed patients (Pirker et al. 1995), thus
demonstrating the thalamus to be an anatomic site of action
of an SSRI.
[
123I]b-CIT is cocaine derivate with high afﬁnity for
DAT (Boja et al. 1995) as well as for 5-HTT (Neumeyer
et al. 1991). In vivo displacement studies in primates have
shown striatal [
123I]b-CIT binding to be predominantly
associated with DAT, whereas, binding in the diencephalon
was mainly associated with 5-HTT (Innis et al. 1991;
Laruelle et al. 1993). [
123I]b-CIT has been shown to be
useful in monitoring the dopaminergic degeneration of the
nigrostriatal pathway in PD (Innis 1994; Tissingh et al.
1998), but it may be also used to assess the integrity of
thalamic 5-HTT (De Win et al. 2005).
In the light of these data we chose to investigate
5-HTT binding in the thalamic area by means of [
123I]
b-CIT SPECT. The primary aim of this study was to
assess whether in PD thalamic 5-HTT binding is
decreased in vivo. Consequently, we investigated thalamic
5-HTT binding as well as striatal DAT binding in 32
unrelated drug-naı ¨ve early PD patients and in 13 healthy
subjects using [
123I]b-CIT SPECT. Additionally, we
hypothesized that 5-HTT binding declines as disease
progresses. In order to verify this hypothesis we repeated
scans on 26 patients in an average of 17 months later.
Finally, we investigated whether 5-HTT loss affects PD
phenotypic heterogeneity. We postulated that 5-HTT loss
may be associated with the presence of tremor and
depression at disease onset.
Materials and methods
Subjects
We studied 32 drug-naı ¨ve early-stage PD patients as well
as 13 healthy volunteers. Diagnosis of PD was made
according to UK Brain Bank criteria (Hughes et al. 1992).
Patients were recruited regardless of their phenotype, i.e.,
presence of tremor or depression, as the primary aim of the
study was to investigate whether 5-HTT binding has
decreased in vivo in an early drug-naı ¨ve PD population. A
[
123I]b-CIT follow-up scan was performed on 26 patients
out of the initial group over a period (mean ± SD) of
17 ± 9 months. At baseline, all patients were drug-naı ¨ve
for dopaminergic treatment and two patients used benzo-
diazepines, whereas, at follow-up, they had initiated
dopaminergic medication (levodopa or a D2 agonist).
PD patients with dementia were not included: a Mini-
Mental State Examination (MMSE) score below 26 was
used as an exclusion criterion.
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part of the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS-III). Based on UPDRS tremor scores (total score
on item 20), we categorized patients in two subgroups: PD
patients with moderate/severe tremor at onset (PDT sub-
group; tremor score C 2 in at least one limb) and PD
patients without tremor at onset (PDWT subset; tremor
score of 0). Note that all patients with tremor had a score
equal to zero on item 21: they revealed resting but no
action tremor during clinical examination. The two groups
displayed no signiﬁcant difference in rigidity and brady-
kinesia UPDRS scores (items 18, 19, 22, 27, 28, 29, 30
and 31). In contrast, patients (n = 12) who had a UPDRS
tremor score of 1 were not included in any of the subset.
At the time of the ﬁrst scan, the Beck Depression
Inventory scale (BDI) was used to assess depressive
symptoms (Visser et al. 2006). See Table 1 for details on
demographic and clinical data of the participants.
Patients were recruited at the VU University Medical
Center (VUMC), Movement Disorders Clinic. The Hospi-
tal Ethics Committee approved the study and all patients
signed informed consent forms.
SPECT procedure
SPECT studies were performed using a brain-dedicated
system, the Strichmann Medical Equipment 8109. The
Strichmann camera system consists of 12 individual
crystals, each equipped with a focusing collimator. The
transaxial resolution is 7.6 mm full-width at half-maximum
(FWHM) (Vermeulen et al. 1995). The energy window was
set at 135–190 keV. Subjects received potassium iodine
orally to block thyroid uptake of free radioactive iodine.
[
123I]b-CIT (speciﬁc activity of[185 MBq/nmol; radio-
chemical purity[99%) was injected intravenously as a
bolus, at a dose of approximately 110 MBq. [
123I] labeling
of b-CIT was performed as described earlier (Tissingh
et al. 1998).
SPECT image acquisition was performed 24 h after
injection, a time point at which [
123I]b-CIT binding to
striatal DAT and thalamic 5-HTT is in an equilibrium state
(Pirker et al. 2000). Slices were acquired during 300 s
periods from the orbitomeatal line to the vertex with an
interslice distance of 10 mm. Data acquisition took place in
a 128 9 128 matrix. Attenuation correction and recon-
struction of the images were performed as described earlier
(Booij et al. 1997a, b).
Data processing
Analysis of the [
123I]b-CIT binding was performed on two
contiguous transverse slices representing the most intense
striatal and thalamic binding. A standard region of interest
(ROI) template was manually drawn with the aid of a
stereotactic atlas. In order to distinguish the forebrain from
the brainstem, we deﬁned the striatal inferior level to be the
anatomic limit between the midbrain and the thalamic
region.
Speciﬁc striatal [
123I]b-CIT binding to DAT in whole
striatum, putamen and caudate nucleus and speciﬁc tha-
lamic [
123I]b-CIT binding to 5-HTT were calculated using
the formula:
meancountsinspecificROI ðÞ ½
  meancountsinnon   specificROI ðÞ  
= meancountsinnon   specificROI ðÞ
This formula is referred as the speciﬁc to non-speciﬁc
[
123I]b-CIT binding ratio (SNS binding ratio). The occipital
region was chosen as reference region because of negligi-
ble density for both DAT and 5-HTT (Laruelle et al.
1994a).
Table 1 Demographic and
clinical data of the participants
PD Parkinson’s Disease, PDT
PD patients subgroup with
moderate/severe tremor at
onset, PDWT PD patients
subgroup without tremor at
onset, SD standard deviation
§§ data not available
Baseline 17 months follow-up
Co
(n = 13)
PD
(n = 32)
PDT
(n = 8)
PDWT
(n = 12)
PD
(n = 26)
PDT
(n = 6)
PD WT
(n = 11)
Sex (male) 8 22 5 5 17 4 5
Age (years, mean ± SD) 53 ± 85 4 ± 10 55 ± 95 6 ± 10 56 ± 95 4 ± 95 8 ± 7
Disease duration
(years, mean ± SD)
§§ 2 ± 12 ± 12 ± 14 ± 14 ± 14 ± 1
UPDRS motor score §§ 18 ± 71 6 ± 61 9 ± 8§ § § § § §
UPDRS tremor score (item 20) §§ 1 ± 13 ± 1 0 §§ §§ §§
UPDRS bradykinesia/rigidity score
(items:18 + 19 + 22 + 27 +
28 + 29 + 30 + 31)
§§ 13 ± 69 ± 61 3 ± 6§ § § § § §
BDI score §§ 8 ± 67 ± 78 ± 6§ § § § § §
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123I]b-CIT binding ratio between
the various groups was expressed as a percentage and
calculated as follows:
GroupXSNS   GroupYSNS ðÞ   GroupXSNS ½    100%:
The investigator performing ROI analysis was blind to
the subjects’ diagnosis as well as demographics.
Statistical analysis
Statistical analysis was performed using the SPSS 13.0
software package. An independent sample t test with equal
variances not assumed was used to investigate the variation
in mean [
123I]b-CIT binding values between PD patients
and healthy control subjects. We compared [
123I]b-CIT
binding values between PDT and PDWT cohorts using one-
way Analysis of Variance (ANOVA). A paired simple two
tailed t test was used to examine the change between the
same group imaging results analyzed at baseline and at
follow-up (i.e., PD patients, PDT and PDWT subgroup). The
Kolmogrov–Smirnov and the Levene’s test were applied
to screen for normality and equal variance, respectively.
Additionally, to increase statistical power, we attempted to
normalize PD putamen and PDWT striatum binding values
with an algorithmic [log10(x + 1)] and an inverse (1/x)
transformation, respectively. Conversely, putamen and
thalamic binding values of the PDT cohort at follow-up
could not be normalized using these transformations, thus
were compared to the respective values of the PDT cohort
at baseline using The Mann–Whitney test. The latter was
also used to compare putamen and thalamic binding values
of the PDT and PDWT subgroup at follow-up.
Pearson bivariate correlation was used to correlate BDI
scores with thalamic [
123I]b-CIT binding values. BDI
scores were normalized using the formula: log10(x + 1).
One-way ANOVA was applied to examine variations in
mean BDI score between PDT and PDWT subgroups.
Differences between groups were considered signiﬁcant
at a level of p B 0.05.
Results
There was no difference with regard to demographic fea-
tures (age and disease duration) between PD patients and
healthy controls and between the PDT and PDWT cohorts
(Table 1).
PD patients had an average of 61% lower putaminal
SNS [
123I]b-CIT binding ratios than healthy controls.
In addition, average caudate nucleus and whole striatum
SNS binding ratios were also signiﬁcantly lower in PD
patients compared to healthy controls (Table 2). We found
a signiﬁcant reduction of 22% in mean thalamic SNS
[
123I]b-CIT binding ratio in PD patients versus healthy
controls (Table 2). Interestingly, mean SNS thalamic
binding ratio was signiﬁcantly lower in the PDT as com-
pared to the PDWT cohort by 19% (Table 2, Fig. 2).
Conversely, there was no signiﬁcant difference in whole
striatum, putamen and caudate nucleus average SNS
binding ratios between PDT and PDWT (Table 2).
Average putaminal SNS [
123I]b-CIT ratio in repeated
scans showed a signiﬁcant decline of 17% from the base-
line (Table 3). Notably, we found that thalamic SNS
[
123I]b-CIT binding ratio was signiﬁcantly further
decreased at follow-up as compared to the PD baseline
measurement by 29% (Table 3; Fig. 1). Note that there was
no signiﬁcant difference in thalamic SNS binding ratios
between PDT and PDWT subgroups at the time of the sec-
ond [
123I]b-CIT SPECT (Fig. 2). Whereas, there was no
signiﬁcant difference in putaminal and thalamic radiotracer
binding between PDT cohort at baseline, and at follow-up
putaminal and thalamic [
123I]b-CIT binding was signiﬁ-
cantly decreased in the PDWT subgroup at the time of
the second as compared to the ﬁrst scan (19 and 39%,
respectively) (Table 3; Fig. 2).
Thalamic SNS binding ratios did not correlate with BDI
scores and there was no difference in BDI score between
PDT and PDWT (Table 1).
Discussion
We found that mean [
123I]b-CIT SPECT putaminal binding
was reduced in all early PD patients at baseline as well as
at follow-up. This is in agreement with ﬁndings from
previous studies (Booij et al. 1997a; Tissingh et al. 1998)
and with the clinical PD diagnosis. Moreover, average
thalamic 5-HTT binding was decreased in early drug-naı ¨ve
PD patients compared to controls and declined as the dis-
ease proceeded. The PDT cohort displayed a lower 5-HTT
thalamic binding when compared to the PDWT cohort at
baseline, while no difference could be detected during
follow-up. Finally, in the PDWT subgroup a further decline
in both putaminal and thalamic binding was detected at
follow-up, which was not true for the PDT subgroup.
To our knowledge, this is the ﬁrst longitudinal study to
investigate 5-HTT loss in PD. Van Dyck et al. (2000)
reported a mean 4.2% per decade age-related decline of 5-
HTT in the diencephalon of healthy humans by means of
[
123I]b-CIT SPECT. However, this decay rate is much
lower that the one we presently reported in PD patients
(29% over 17 months). Therefore, whereas 5-HTT loss
may occur with age on a physiological basis, consistent
with our results its decay appears more severe in PD
patients. These data conﬁrm the ﬁrst two hypotheses we
stated, according to our results 5-HTT is decreased in PD
724 J Neural Transm (2008) 115:721–729
123and further declines along with the disease. Noteworthy, it
has been argued that [
123I]b-CIT radiotracer in the thala-
mus may bind to monoaminergic transporters other than
5-HTT. In particular, in a monkey PET study (Farde et al.
1994) citalopram as well as desipramine, a norepinephrine
transporter (NET) blocker, was able to displace thalamic
[
123I]b-CIT binding by 50 and 40%, respectively. Con-
versely, Laruelle et al. (1993) demonstrated that the
selective NET inhibitor maprotiline failed to affect [
123I]b-
CIT binding in monkey diencephalon. Additionally, con-
cerning SPECT studies in humans, De Win et al. (2005)
validated [
123I]b-CIT to assess in vivo 5-HTT in the
thalamic area. Importantly, in this study, a double-blind,
placebo-controlled, crossover design with citalopram (the
most selective 5-HTT blocker) was performed. Moreover,
it has been demonstrated that citalopram blocks approxi-
mately 50% of thalamic [
123I]b-CIT binding in depressed
patients (Pirker et al. 1995). Interestingly, in a recent study
(Shang et al. 2007), venlafaxine (a 5-HTT and NET
inhibitor) proved to decrease [
123I]b-CIT SPECT binding
by 54%, an outcome similar to the one obtained by Pirker
et al. (1995). Therefore, it may be argued that in vivo only
a small part of the [
123I]b-CIT binding to human thalamus
is due to NET binding. Finally, it must be taken into
account that in the human brain 5-HTT is much higher than
NET thalamic concentration (Tong et al. 2007), while the
afﬁnity of [
123I]b-CIT (or RTI-55) for NET is lower than
for 5-HTT (Scheffel et al. 1997). To summarize, although
we cannot exclude that in vivo [
123I]b-CIT binding in the
human thalamus, may be partly due to NET binding; the
largest part likely represents 5-HTT binding. Nonetheless,
Table 2 Mean speciﬁc to non-speciﬁc [
123I]b-CIT binding ratios (mean ± SD) assessed at baseline
Region of interest Baseline
Controls (n = 13) PD patients (n = 32) PDT (n = 8) PDWT (n = 12)
Striatum, whole 8.65 ± 2.61 4.39 ± 1.10* 4.38 ± 0.95 4.21 ± 1.45
Caudate, whole 9.43 ± 2.55 6.34 ± 1.55* 5.60 ± 0.98 6.93 ± 1.93
Putamen, whole 7.72 ± 2.65 3.02 ± 0.85* 3.08 ± 0.79 2.87 ± 1.10
Thalamus, whole 1.98 ± 0.56 1.55 ± 0.34* 1.37 ± 0.37 1.70 ± 0.33*
* Signiﬁcant difference between controls and PD patients (*p B 0.02) and between PDT and PDWT patients (p = 0.05)
PD Parkinson’s disease, PDT PD patients subgroup with moderate/severe tremor at onset, PDWT PD patients subgroup without tremor at onset,
SD standard deviation
Table 3 Mean speciﬁc to non-speciﬁc [
123I]b-CIT binding ratio (mean ± SD) at baseline and at follow-up (17 ± 9 months later)
Region of
interest
Baseline PD
(n = 26)
Follow-up PD
(n = 26)
Baseline PDT
(n = 6)
Follow-up PDT
(n = 6)
Baseline PDWT
(n = 12)
Follow-up PDWT
(n = 11)
Striatum, whole 4.17 ± 0.95 3.86 ± 0.75 4.16 ± 0.98 3.79 ± 0.42 3.91 ± 1.1 3.64 ± 0.73
Caudate, whole 6.13 ± 1.47 5.60 ± 1.36 5.88 ± 1.36 5.65 ± 0.68 5.76 ± 1.58 5.52 ± 1.16
Putamen, whole 2.84 ± 0.71 2.36 ± 0.51* 2.83 ± 0.52 2.37 ± 0.29 2.74 ± 0.93 2.22 ± 0.40*
Thalamus, whole 1.50 ± 0.35 1.07 ± 0.39* 1.26 ± 0.34 1.16 ± 0.29 1.65 ± 0.31 1.00 ± 0.45*
* Signiﬁcant difference between PD patients at baseline and at follow-up (p\0.01) and between PDWT subgroup at baseline and at follow-up
(p\0.05)
PD Parkinson’s disease, PDT PD patients subgroup with moderate/severe tremor at onset, PDWT PD patients subgroup without tremor at onset,
SD standard deviation
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Fig. 1 Scatterplot showing the rate of change in thalamic speciﬁc to
non-speciﬁc [
123I]b-CIT binding ratio in healthy controls and in PD
patients at baseline and at follow-up. At the time of the ﬁrst imaging
series, mean thalamic [
123I]b-CIT binding ratio was signiﬁcantly
lower in PD patients as compared to controls (p = 0.02). Moreover,
mean thalamic ratio obtained in PD patients was signiﬁcantly lower at
the follow-up as compared to the baseline (p\0.01). Second scan
data were obtained an average of 17 month later. PD baseline and PD
follow-up indicate PD patients at baseline and at the follow-up,
respectively
J Neural Transm (2008) 115:721–729 725
123further studies with selective radiotracers for 5-HTT are
needed to reproduce our ﬁndings. In this context, two
previous PET studies with selective 5-HTT tracers found
no signiﬁcant thalamic 5-HTT decrease in PD patients
when compared to controls (Guttman et al. 2007; Kerenyi
et al. 2003). In particular, Kerenyi et al. describe a trend for
lower thalamic 5-HTT binding with a decrease of
approximately 25%, a range loss similar to the one we
presently report (22%). Importantly, the small number of
participants investigated in the PET studies mentioned
above (9 and 13, respectively) may have played a role for a
non-signiﬁcant thalamic decreased binding outcome. This
may be relevant to the present study where a thalamic 5-
HTT decline over time was demonstrated in a larger cohort
of 26 PD patients.
At baseline, we found lower thalamic 5-HTT density in
PD patients with mild to severe tremor compared to
patients without tremor. The two cohorts (PDT and PDWT)
differed in terms of UPDRS tremor scores but were com-
parable in terms of rigidity and bradykinesia. In fact, PDT
had a UPDRS resting tremor score C2 in at least one limb,
whereas, the PDWT presented no tremor at all. Resting
tremor was the only one out of the cardinal motor features
that clinically characterize PD (tremor, bradykinesia,
rigidity and postural instability) to differentiate the two
patient subsets. Moreover, the absence of signiﬁcant dif-
ferences in striatal DAT binding between the two
subgroups conﬁrms the assumption we made based on
previous studies: bradykinesia and rigidity but not tremor
correlates with striatal DAT binding (Spiegel et al. 2006).
These data suggest that 5-HT may play a role in the eti-
ology of resting tremor in early PD stages. In this context,
Haapaniemi et al. reported a lower thalamic [
123I]b-CIT
binding in PD compared to controls, although, in contrast
with our results, no correlation to tremor scores was
detected (Haapaniemi et al. 2001). Difference in results
may be due to measuring methods. We obtained data 24 h
post-injection, whereas they acquired scans at 4 h post-
injection. Although there is still considerable debate as to
the best timing to acquire SPECT images (Brucke et al.
1993; Laruelle et al. 1994b), scans obtained between 20
and 24 h showed to be closer to a state of transient equi-
librium (Pirker et al. 2000).
Recently, Doder et al. (2003) reported a reduction of in
vivo raphe 5-HT1A binding in PD patients and an associ-
ation with the severity of UPDRS tremor scores using
11C-
WAY 100635 PET. The authors suggested that this
reduction expresses loss of 5-HT cell bodies, possibly due
to Lewy body degeneration. Our present ﬁnding indicating
thalamic [
123I]b-CIT binding decline is in agreement with
this hypothesis, since the 5-HTT is located exclusively
on the 5-HT neuronal membrane. Alternatively, 5-HT
and dopaminergic activity may decline in parallel in the
striatum and in the midbrain of parkinsonian patients,
particularly in patients with tremor onset. Reduced sero-
tonergic function would result in less inhibition and in
turn facilitate striatal dopamine release (De et al. 2004;
Di, V et al. 2002; Jacobs et al. 1993). We investigated PD
patients at onset, and did not investigate radiotracer bind-
ing within raphe nuclei; whereas Doder et al. examined
participants at an advanced stage and did not analyze the
thalamic area. Note that unlike their study, we chose not to
correlate thalamic binding to UPDRS total tremor scores.
In fact, patients we enrolled were at an early stage and thus
presented a very low total tremor score (mean items 20
total score ± SD = 1 ± 1). Due to such a low variance in
total tremor score, a correlation between these values and
SNS thalamic binding could not have been evaluated
adequately. Also note that both studies did not take into
account 5-HTT levels in striatal and cortical regions, which
express low to moderate 5-HTT concentrations. According
to Braak et al. (2003) midbrain stem is the ﬁrst component
of the somato-motor and emotional motor system to be
affected, whereas, the degeneration of cells in the sub-
stantia nigra, thalamic nuclei and neocortical areas follows.
In the light of this evidence, a comparison between 5-HTT
availability among brain areas presenting 5-HTT in sub-
sequent PD stages by means of selective 5-HTT tracers is
warranted to better assess the role of 5-HT in PD. In fact,
although in PD alterations of striatal and cortical 5-HTT
may be associated with tremor, in the present study we
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Fig. 2 Scatterplot showing the rate of change in thalamic speciﬁc to
non-speciﬁc [
123I]b-CIT binding ratio in the PDWT as compared to the
PDT subgroup over time. Mean thalamic [
123I]b-CIT binding ratio
was signiﬁcantly lower in the PDT versus the PDWT subgroup at
baseline (p = 0.05). No difference in mean thalamic ratio between
the PDT and the PDWT subset was detected at the time of the second
imaging series. Moreover, mean thalamic ratio in the PDWT subgroup
was signiﬁcantly lower at follow-up than at baseline (p\0.01).
Conversely no difference was found in the PDT subset. Second scan
data PDTwere obtained in an average of 17 month later. PDT and
PDWT indicate PD patients subgroups with moderate/severe tremor
and without tremor at onset, respectively
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123were not able to assess striatal 5-HTT binding, as [
123I]b-
CIT binds predominantly to DAT in the striatum (Laruelle
et al. 1993). Additionally, although we provided some
evidence that [
123I]b-CIT SPECT may be used to measure
5-HTT in 5-HTT-low cortical areas, these measurements
must be interpreted with caution (De Win et al. 2005).
Unlike baseline imaging, the repeated scans showed no
statistical difference in thalamic 5-HTT binding between
the PDWT and PDT group. Furthermore, the PDWT sub-
group revealed a faster 5-HTT thalamic decline as
compared to the PDT group. It has been demonstrated that
PD patients, who manifest symptoms at a relatively [
123I]b-
CIT high density, progress substantially faster than those
who manifest symptoms at a lower transporter density
(Seibyl et al. 1999). While we do not have an explanation
for this phenomenon, a progressive loss of surviving neu-
rons could be postulated. Both Lewy body degeneration
and reduced 5-HTT inhibiting activity over the striatum
might have a major effect in those patients still presenting
with a high transporter density. Additionally, we were not
able to assess whether tremor had eventually revealed in
the PDWT subgroup at the time of the second scan, as
patients were under dopaminergic treatment. Indeed the
lack of follow-up UPDRS clinical examinations represents
a limitation of our study.
5-HT neurotransmission is impaired in PD, but its causal
relationship with tremor remains controversial and it is
unclear what the clinical relevance of a 22% thalamic 5-
HTT loss is. Due to the design of the present study, our
ﬁndings do not allow a deﬁnitive answer on PD tremor but
certainly supports the role of 5-HTT function.
As of yet, [
123I]b-CIT SPECT imaging correlating 5-
HTT binding decline to depressive symptoms in PD has
revealed inconsistent results. Kim et al. (1999) reported no
signiﬁcant correlation between hypothalamic/midbrain 5-
HTT in PD and UPDRS-I (depression items). A further
study showed no relationship between 5-HTT binding and
UPDRS rating of mood in thalamus, but detected a sig-
niﬁcant correlation in dorsal midbrain (Murai et al. 2001).
Finally, Haapianemi and colleagues demonstrated that 5-
HTT frontal region binding in PD correlates to UPDRS-I
(Haapaniemi et al. 2001). In the present study, we found no
correlation between BDI scores and thalamic 5-HTT and,
even more importantly, there was no difference in BDI
between the PDT and PDWT subgroups suggesting no
contribution of depressive symptoms to these ﬁndings.
Whereas, we used BDI, a reliable self-assessment scale to
assess depression in PD (Visser et al. 2006), other studies
used UPDRS rating for mood, which is a less speciﬁc
screening tool. We did not assess BDI at the follow-up,
therefore depressive symptoms may not have been revealed
until a more advanced stage, along with thalamic 5-HTT
decline.
In conclusion, in this study we show loss of thalamic 5-
HTT binding in PD and its progressive loss over an average
of 17 months. At baseline, a decreased thalamic 5-HTT
density in patients presenting tremor at onset was found,
while no correlation could be detected between thalamic
[
123I]b-CIT binding ratios and BDI scores. In this context,
further studies with selective 5-HTT tracers are needed to
reproduce our ﬁndings in early PD. Additionally, new
research is warranted to gain a better insight into the causal
relation that links 5-HT dysfunction and tremor and
depression in PD. Finally, pharmacological challenges with
serotonergic agents may be performed to test their potential
capacity in counteracting PD tremor.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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